Why Is Finisar Suffering?

Recs

1

I bet you want me to tell you why Finisar's (Nasdaq: FNSR) share price was cut off at the kneecaps yesterday. The optical networking component maker's report really wasn't bad. The product is used by information storage companies like EMC (NYSE: EMC).

Sorry. Can't help you. But I'll try anyway.

Finisar revenue increased about 5% year over year from approximately $107 million to $112 million. However, the company's non-GAAP earnings per share dropped from $0.04 to $0.02. Nevertheless, Finisar met analyst expectations of $0.02 in adjusted earnings per share. Like Google and Berkshire Hathaway, Finisar doesn't play the earnings guidance game, so that's not the culprit. The revenue forecast it does provide was positive, and the executives sounded downright upbeat in the conference call, talking about growth opportunities like data center virtualization. You can't even blame the drop on analyst downgrades -- there weren't any.

How about sudden competitive pressures, then? Nope -- no major optical networking news from JDS Uniphase (Nasdaq: JDSU), Cisco (Nasdaq: CSCO), or Brocade (Nasdaq: BRCD), and all of those stocks traded markedly sideways yesterday.

Given the stock chart yesterday, it seems likely that a major shareholder unloaded some stock on the open market. Fidelity Investments owned 13.4% of the outstanding stock at the end of 2007, and T. Rowe Price (Nasdaq: TROW) held 9.1%, putting them in the lineup of usual suspects. Price doesn't seem too hard-pressed for liquidity these days, but $18 billion flowed out of privately held Fidelity's mutual funds last year. Maybe that's the backbreaker.

In the end, the exact reason doesn't really matter. The facts we have in front of us say that there's nothing wrong with Finisar's business, and we really shouldn't look this spurious and curious bargain price in the mouth. The discount moment will pass while we wait and ponder the cosmic relevance of intraday trading volume spikes on no relevant news. Leave the rocket science to the rocket scientists, and just ride the rocket.

Further Foolishness:

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 591696, ~/Articles/ArticleHandler.aspx, 11/10/2009 7:17:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Health-Care Reform: A Tale of Two Chambers

Related Tickers

11/9/2009 4:00 PM
EMC $17.01 Up +0.28 +1.67%
EMC Corp CAPS Rating: ****
BRCD $9.24 Up +0.25 +2.78%
Brocade Communicat… CAPS Rating: ***
CSCO $23.99 Up +0.17 +0.71%
Cisco Systems, Inc… CAPS Rating: ****
FNSR $8.17 Up +0.17 +2.13%
Finisar Corp CAPS Rating: ***
JDSU $6.94 Up +0.48 +7.43%
JDS Uniphase Corp CAPS Rating: ***
TROW $50.99 Up +1.01 +2.02%
T. Rowe Price Grou… CAPS Rating: ***

Community: Investing Wiki

Term Of The Hour

Biotechnology: Biotechnology uses biological processes to solve problems in such areas as health and medicine, agriculture and manufacturing.

Want to learn more or edit this definition?
Click here to read more!